Home  |  Contact

UniProtKB/Swiss-Prot P20823: Variant p.Gly31Asp

Hepatocyte nuclear factor 1-alpha
Gene: HNF1A
Variant information

Variant position:  31
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glycine (G) to Aspartate (D) at position 31 (G31D, p.Gly31Asp).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to medium size and acidic (D)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In MODY3; no effect on interaction with PCBD1 and DNA.
Any additional useful information about the variant.



Sequence information

Variant position:  31
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  631
The length of the canonical sequence.

Location on the sequence:   ELLAALLESGLSKEALIQAL  G EPGPYLLAGEGPLDKGESCG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ELLAALLESGLSKEALIQALGEPGPYLLAGEGP-------LDKGESCG

Mouse                         ELLAALLESGLSKEALIQALGEPGPYLMVGEGP-------L

Rat                           ELLAALLESGLSKEALIQALGEPGPYLMVGDGP-------L

Chicken                       ELLGALLESGLTKETLIKGLSEAEPYVLQSESQHAINALQT

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 631 Hepatocyte nuclear factor 1-alpha
Domain 1 – 32 HNF-p1
Region 1 – 31 Dimerization
Alternative sequence 1 – 117 Missing. In isoform 6.


Literature citations

Mutation screening in 18 Caucasian families suggest the existence of other MODY genes.
Chevre J.-C.; Hani E.H.; Boutin P.; Vaxillaire M.; Blanche H.; Vionnet N.; Pardini V.C.; Timsit J.; Larger E.; Charpentier G.; Beckers D.; Maes M.; Bellanne-Chantelot C.; Velho G.; Froguel P.;
Diabetologia 41:1017-1023(1998)
Cited for: VARIANTS MODY3 ASP-31; TRP-159; THR-161; TRP-200 AND TRP-271;

Structural basis of dimerization, coactivator recognition and MODY3 mutations in HNF-1alpha.
Rose R.B.; Bayle J.H.; Endrizzi J.A.; Cronk J.D.; Crabtree G.R.; Alber T.;
Nat. Struct. Biol. 7:744-748(2000)
Cited for: CHARACTERIZATION OF VARIANTS MODY3 HIS-12; ARG-20 AND ASP-31; FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH PCBD1;

Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain.
Estalella I.; Rica I.; Perez de Nanclares G.; Bilbao J.R.; Vazquez J.A.; San Pedro J.I.; Busturia M.A.; Castano L.;
Clin. Endocrinol. (Oxf.) 67:538-546(2007)
Cited for: VARIANTS MODY3 ASP-31; MET-133; 171-ARG--GLN-631 DEL; GLY-271 AND LEU-447;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.